GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Submission of Matters to a Vote of Security Holders

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

Submission of Matters to a Vote of Security
Holders.

At the 2016 Annual Meeting of Stockholders held on December15,
2016, the stockholders of Galectin Therapeutics Inc. (Galectin or
the Company) re-elected each of the Companys directors that had
been nominated to serve until the next annual meeting or until
their successors are elected and have been qualified. The
stockholders also voted on a non-binding advisory resolution to
approve the compensation paid to the Companys named executive
officers and ratified the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016.

The final results of the voting on each matter of business at the
2016 Annual Meeting are as follows:

Election of Directors

Name

VotesFor

VotesWithheld

BrokerNon-Votes

Gilbert F. Amelio, Ph.D.

10,677,510 573,344 14,976,838

Kevin D. Freeman

11,003,268 247,586 14,976,838

Arthur R. Greenberg

10,826,611 424,243 14,976,838

John Mauldin

10,692,692 558,162 14,976,838

Gilbert S. Omenn, M.D., Ph.D.

10,869,940 380,914 14,976,838

Steven Prelack

10,878,337 372,517 14,976,838

Marc Rubin, M.D.

10,870,558 380,296 14,976,838

Peter G. Traber, M.D.

10,844,660 406,194 14,976,838

Non-binding advisory resolution to approve the compensation
paid to the Companys named executive officers

Votes For

Votes Against

Votes Abstain

Broker Non-Votes

10,263,034

844,997 142,823 14,976,838

Ratification of the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016

Votes For

Votes Against

Votes Abstain

25,457,842

533,163 236,687

Additionally, the holder of the Companys Series B Convertible
Preferred Stock voted as a separate class to nominate and elect
two directors (the Series B Directors). Mr.James Czirr was
re-elected as a Series B Director and Dr.Theodore Zucconi was
elected as a new Series B Director, each to serve until the next
annual meeting or until their successors are elected and have
been qualified. The results of the voting for the Series B
Directors are as follows:

Name

Votes For

Votes Withheld

Broker Non-Votes

James C. Czirr

6,356,932 n/a

Theodore Zucconi

6,356,932 n/a


About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)


An ad to help with our costs